单剂大剂量去甲氧柔红霉素(IDA)联合大剂量阿糖胞苷(Arα-C)治疗18例(男13例。女5例,年龄20～56岁)成人急性淋巴细胞白血病(ALL)。IDA治疗前全部患者接受过Arα-C治疗。其中1例复发,1例初次难治性ALL,16例为难治性复发。9例(50％)为Ph~+ ALL。治疗方案:Arα-C 3g/m~2·d,第1～5天静滴,每次静滴时间至少3小时。第3天静滴IDA,剂量分别为20mg/m~2、30mg/m~2、40mg/m~2和50mg/m~2。 One-dose high-dose idarubicin (IDA) combined with high-dose cytarabine (Arα-C) in 18 patients (13 males, 5 females, aged 20-56 years), adult acute lymphoblastic leukemia ( ALL). All patients before IDA treatment received Arα-C treatment. One case had recurrence, 1 case was refractory to ALL, and 16 cases were refractory to recurrence. Nine patients (50%) were Ph~+ ALL. Treatment plan: Arα-C 3g/m~2·d, intravenous infusion on the first to fifth days. Each infusion time was at least 3 hours. On the third day of intravenous infusion of IDA, the doses were 20 mg/m~2, 30 mg/m~2, 40 mg/m~2, and 50 mg/m~2, respectively.